Skip to main content
. 2015 Jul 17;6(29):27008–27022. doi: 10.18632/oncotarget.4714

Figure 3. Cysteine cathepsin inhibition promotes osteoclast fusion.

Figure 3

a. TRAP staining of osteoclasts differentiated with M-CSF/RANKL in the presence of 50 μM CA074, JPM-OEt or DMSO vehicle control. CD11b+/Gr-1+ 4T1.2 MDSCs and CD11b+/Ly6C+ 4T1.2 MDSCs were isolated from mice with experimental 4T1.2 metastasis. CD11b+/Ly6C+ Naïve MDSCs and total bone marrow were harvested from naïve, non-tumor-bearing mice. Bone marrow cells cultured without RANKL (rightmost column) did not form osteoclasts. b. Dose response of RANKL treatment of naïve total bone marrow cells stimulated with M-CSF and either DMSO or 50 μM JPM-OEt. c. Quantification of surface area of osteoclasts differentiated with increasing doses of CA074 or JPM-OEt. > 250 osteoclasts were measured for each condition. ***p < 0.001 d. SRB proliferation assay of naïve bone marrow cells cultured with M-CSF for 4 days. Error bars represent SEM.